samedan logo
 
 
spacer
home > ebr > winter 2003 > killer apps for killer diseases
PUBLICATIONS
European BioPharmaceutical Review

Killer Apps for Killer Diseases

According to the Organization for Economic Co-Operation and Development, more than 17 million people die of infectious disease each year. Indeed, within the last three decades, no fewer than 30 new communicable diseases have emerged for which no effective treatment exists. Just about every major antibiotic has shown the evolution of resistance within three years of introduction, which means that the list of unmet needs is growing. Can biotechnology buck the trend?

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By G Steven Burrill, CEO of Burrill & Company

G Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM). Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.

spacer
G Steven Burrill
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

EuroBiopartnering 2008

7-9 October 2008, Paris, France

EuroBiOpartnering 2008 gives you the unique opportunity to meet the relevant decision makers and opinion leaders from the international biotech community and offers you 3 days of partnering opportunities including one-to-one meetings, company presentations and further networking activities…
More info >>

 
News and Press Releases

Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement